Search details
1.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood
; 143(16): 1616-1627, 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38215395
2.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet
; 402(10402): 641-654, 2023 08 19.
Article
in English
| MEDLINE | ID: mdl-37295445
3.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood
; 138(10): 836-846, 2021 09 09.
Article
in English
| MEDLINE | ID: mdl-34115103
4.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Article
in English
| MEDLINE | ID: mdl-33259589
5.
Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.
Blood
; 137(15): 2046-2056, 2021 04 15.
Article
in English
| MEDLINE | ID: mdl-33512457
6.
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Am J Hematol
; 98(5): 739-749, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36810799
7.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35810754
8.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Article
in English
| MEDLINE | ID: mdl-32688395
9.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med
; 379(26): 2517-2528, 2018 12 27.
Article
in English
| MEDLINE | ID: mdl-30501481
10.
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
Haematologica
; 106(11): 2845-2852, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-33054118
11.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol
; 188(6): 918-923, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31682002
12.
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
Br J Haematol
; 184(4): 605-615, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30443898
13.
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Lancet Oncol
; 19(4): 486-496, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29475723
14.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Haematologica
; 103(5): 874-879, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29419429
15.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica
; 103(9): 1511-1517, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29880613
16.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Am J Hematol
; 93(11): 1394-1401, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30132965
17.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Lancet Oncol
; 18(2): 230-240, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-28089635
18.
The use of zanubrutinib in chronic lymphocytic leukemia.
Clin Adv Hematol Oncol
; 20(12): 705-708, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36469663
19.
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.
Haematologica
; 106(1): 284-287, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-32079693
20.
Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.
Br J Haematol
; 186(4): 637, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31044417